Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Cooke

Showing results (361-370 of 408) with videos related to

Pageof 41
Sort By:
British Journal of Pharmacology|June 1, 2012
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rateP Gergely, B Nuesslein-Hildesheim, D Guerini, et al.
Molecular Cancer Therapeutics|July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Nature Medicine|April 8, 2015
Studying clonal dynamics in response to cancer therapy using high-complexity barcodingHyo-eun C Bhang, David A Ruddy, Viveksagar Krishnamurthy Radhakrishna, et al.
Journal of Medicinal Chemistry|January 10, 2024
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal MelanomaMichael Visser, Julien P N Papillon, Michael Luzzio, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven TumorsKelli-Ann Monaco, Scott Delach, Jing Yuan, et al.
Nature Medicine|December 24, 2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphomaRami Rahal, Mareike Frick, Rodrigo Romero, et al.
Nature Genetics|October 1, 2013
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemiaJacob D Jaffe, Yan Wang, Ho Man Chan, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 41

Showing results (361-370 of 408) with videos related to

Sort By:
Pageof 41
British Journal of Pharmacology|June 1, 2012
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rateP Gergely, B Nuesslein-Hildesheim, D Guerini, et al.
Molecular Cancer Therapeutics|July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Nature Medicine|April 8, 2015
Studying clonal dynamics in response to cancer therapy using high-complexity barcodingHyo-eun C Bhang, David A Ruddy, Viveksagar Krishnamurthy Radhakrishna, et al.
Journal of Medicinal Chemistry|January 10, 2024
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal MelanomaMichael Visser, Julien P N Papillon, Michael Luzzio, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven TumorsKelli-Ann Monaco, Scott Delach, Jing Yuan, et al.
Nature Medicine|December 24, 2013
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphomaRami Rahal, Mareike Frick, Rodrigo Romero, et al.
Nature Genetics|October 1, 2013
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemiaJacob D Jaffe, Yan Wang, Ho Man Chan, et al.
Journal of Medicinal Chemistry|May 31, 2017
Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant CancersGisele A Nishiguchi, Alice Rico, Huw Tanner, et al.
Journal of Medicinal Chemistry|May 7, 2019
Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the ClinicSavithri Ramurthy, Benjamin R Taft, Robert J Aversa, et al.
Pageof 41